Advances in the Treatment of Nonmetastatic Non–Small Cell Lung Cancer
Search for other papers by Jonathan W. Riess in
Current site
Google Scholar
PubMed
Search for other papers by Joyce S. Lee in
Current site
Google Scholar
PubMed
Based on the results of several clinical trials, neoadjuvant, adjuvant, and perioperative PD-1/PD-L1 immune checkpoint inhibitor therapies were established as standards of care in the treatment of stage IIA–III resectable non–small cell lung cancer (NSCLC), in the absence of driver alterations, such as EGFR mutations and ALK fusions, and contraindications. Patients harboring common EGFR mutations (E19del or L858R) or ALK fusions have also been found to benefit from targeted therapies in the adjuvant setting. As the treatment landscape continues to expand, the prevention and control of adverse events must be prioritized to maximize patient benefit. The NCCN Guidelines for NSCLC reflect the most up-to-date, evidence-based data relating to the treatment of nonmetastatic NSCLC and immunotherapy-related toxicities.
Disclosures: Dr. Riess has disclosed receiving honoraria from Amgen, Bristol Myers Squibb, Catalyst Pharmaceuticals, Genentech, Inc., GSK plc, Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Merus N.V., Pfizer Inc., and Regeneron Pharmaceuticals; receiving grant/research support from ArriVent BioPharma, AstraZeneca Pharmaceuticals, Boehringer Ingelheim GmbH, IO Biotech, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Nuvalent, Inc., Prelude Therapeutics, Revolution Medicines, Seagen Inc., and Summit Therapeutics Inc.; and receiving consulting fees from Daiichi Sankyo and OncoHost. Dr. Lee has disclosed no relevant financial relationships.
© 2019-2024 National Comprehensive Cancer Network